What is the pathophysiology of Alzheimer's disease (AD) and how does it cause behavioral changes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Alzheimer's disease causes behavioral changes due to progressive brain degeneration involving abnormal protein accumulation and neuronal death, as evidenced by the most recent study in 2021 1. The disease begins with the formation of beta-amyloid plaques outside neurons and tau protein tangles inside them, primarily affecting the hippocampus and cerebral cortex. These pathological changes disrupt neural connections and neurotransmitter systems, particularly acetylcholine, which is crucial for memory and cognition. As the disease advances, it damages brain regions controlling emotions, judgment, and social behavior, leading to a range of behavioral symptoms, including agitation, aggression, depression, apathy, wandering, and personality changes, as noted in a study from 2021 1. The prefrontal cortex deterioration impairs decision-making and impulse control, while amygdala involvement affects emotional regulation. Patients may experience sleep disturbances due to disruption of circadian rhythm regulation, and language centers deterioration leads to communication difficulties, causing frustration and behavioral outbursts. The patient's diminishing ability to interpret their environment correctly (agnosia) creates confusion and fear-based reactions, as described in a study from 2015 1. These behavioral symptoms often fluctuate throughout the day, with "sundowning" (increased confusion and agitation in late afternoon/evening) being common due to fatigue and disrupted biological rhythms. Some key points to consider include:

  • The formation of beta-amyloid plaques and tau protein tangles as the primary pathological changes in Alzheimer's disease
  • The disruption of neural connections and neurotransmitter systems, particularly acetylcholine
  • The damage to brain regions controlling emotions, judgment, and social behavior
  • The range of behavioral symptoms that can occur, including agitation, aggression, depression, apathy, wandering, and personality changes
  • The importance of understanding these pathophysiological mechanisms in explaining why behavioral changes are a fundamental aspect of Alzheimer's disease progression, as highlighted in a study from 2021 1.

From the Research

Pathophysiology of Alzheimer's Disease

The pathophysiology of Alzheimer's disease (AD) is complex and involves the accumulation of amyloid-β plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein, leading to neurodegeneration and dementia 2, 3. The soluble forms of amyloid-β and tau work together to drive healthy neurons into the diseased state, with amyloid-β triggering the conversion of tau from a normal to a toxic state 2.

Behavioral Changes in Alzheimer's Disease

Behavioral changes are a common feature of AD, with 88% of patients exhibiting measurable behavioral changes, including apathy, agitation, anxiety, irritability, and dysphoria 4. These behavioral changes are significantly correlated with cognitive impairment, with agitation, dysphoria, apathy, and aberrant motor behavior being the most common behaviors associated with cognitive decline 4.

Key Players in Alzheimer's Disease Pathogenesis

  • Amyloid-β: triggers the conversion of tau from a normal to a toxic state, leading to neurodegeneration 2
  • Tau: plays a detrimental pathological role in AD, with abnormal hyperphosphorylation leading to neurodegeneration 3
  • Presenilins and apolipoprotein E: involved in the pathogenesis of AD, with presenilins contributing to the production of amyloid-β and apolipoprotein E influencing the risk of developing AD 5

Therapeutic Strategies

Current therapeutic strategies for AD focus on symptomatic treatment, with acetylcholinesterase inhibitors and memantine providing modest benefits on cognition 6. However, novel approaches targeting the amyloid cascade hypothesis and tau protein may hold promise for disease-modifying treatments 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Role of tau protein in Alzheimer's disease: The prime pathological player.

International journal of biological macromolecules, 2020

Research

[Alzheimer's disease as neurodegenerative disorder].

Postepy higieny i medycyny doswiadczalnej (Online), 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.